Your shopping cart is currently empty

NIK-IN-3 is a potent, orally active inhibitor of NF-κB-inducing kinase (NIK) with an IC50 value of 5.2 nM. It effectively suppresses activation of the non-canonical NF-κB pathway and inhibits the secretion of pro-inflammatory cytokines, including TNF-α, IL-6, IL-1β, and the chemokine CXCL12. NIK-IN-3 demonstrates significant anti-inflammatory effects in LPS-induced sepsis and DSS-induced colitis mouse models. This compound is applicable in inflammation-related research, such as studies on colitis.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | NIK-IN-3 is a potent, orally active inhibitor of NF-κB-inducing kinase (NIK) with an IC50 value of 5.2 nM. It effectively suppresses activation of the non-canonical NF-κB pathway and inhibits the secretion of pro-inflammatory cytokines, including TNF-α, IL-6, IL-1β, and the chemokine CXCL12. NIK-IN-3 demonstrates significant anti-inflammatory effects in LPS-induced sepsis and DSS-induced colitis mouse models. This compound is applicable in inflammation-related research, such as studies on colitis. |
| Targets&IC50 | NF-κB:5.2 nM |
| In vitro | NIK-IN-3 (Compound 38) effectively inhibits the activation of the non-canonical NF-κB pathway in HEK293 cells at concentrations between 1-5 μM. At 100 nM over 3 days, it suppresses Th17 cell differentiation in murine naive CD4+ T cells without significant cytotoxicity. Additionally, at 5 μM for 22 hours, NIK-IN-3 inhibits the secretion of inflammatory factors such as TNF-α, IL-6, IL-1β, and CXCL12 in LPS and CD40-induced RAW264.7 cells. |
| In vivo | NIK-IN-3 (Compound 38) administered intraperitoneally at 10 mg/kg enhances survival rates and decreases inflammation in mice models of LPS-induced sepsis by inhibiting the non-canonical NF-κB pathway. Additionally, oral administration of NIK-IN-3 at 25-50 mg/kg once daily for 7 days alleviates colitis symptoms in C57BL/6 mice (DSS-induced colitis model). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.